Journal article
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
YY Lim, VL Villemagne, SM Laws, D Ames, RH Pietrzak, KA Ellis, KD Harrington, P Bourgeat, O Salvado, D Darby, PJ Snyder, AI Bush, RN Martins, CL Masters, CC Rowe, PJ Nathan, P Maruff
Neurobiology of Aging | ELSEVIER SCIENCE INC | Published : 2013
Abstract
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimer's disease (AD)-related cognitive impairment. We aimed to determine the relationship between BDNF Val66Met and beta-amyloid (Aβ) on cognitive decline, hippocampal atrophy, and Aβ accumulation over 36 months in 165 healthy adults enrolled in the Australian Imaging, Biomarkers and Lifestyle study. In healthy adults with high Aβ, Met carriers showed significant and moderate-to-large declines in episodic memory, executive function, and language, and greater hippocampal atrophy over 36 months, compared with Val/Val homozygotes. BDNF Val66Met was not found to be related to rates of change in c..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
Funding for the study was provided in part by the study partners [Australian Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd., Hollywood Private Hospital, Sir Charles Gardner Hospital]. The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF). The authors also acknowledge the financial support of the Cooperative Research Centre (CRC) for Mental Health, from the Australian Government.